DNA-PK inhibition overcomes resistance to oncolytic virotherapy
Translational Research · 2026-12 · 298 · 210-225
DOI: 10.1016/j.trsl.2026.10.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2026-12. Verfasst von Xiao Xiao und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang 421001, China; Department of Pharmacology, Zhongsh…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, DNA-Activated Protein Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation.
Abstract (Originalsprache)
Oncolytic virotherapy is a promising therapeutic strategy that uses replication-competent viruses to selectively destroy malignancies. However, the therapeutic effect of certain oncolytic viruses (OVs) varies among cancer patients. Thus, it is necessary to overcome resistance to OVs through rationally designed combination strategies. Here, through an anticancer drug screening, we show that DNA-dependent protein kinase (DNA-PK) inhibition sensitizes cancer cells to OV M1 and improves therapeutic effects in refractory cancer models in vivo and in patient tumour samples. Infection of M1 virus triggers the transcription of interferons (IFNs) and the activation of the antiviral response, which can be abolished by pretreatment of DNA-PK inhibitor (DNA-PKI), resulting in selectively enhanced replication of OV M1 within malignancies. Furthermore, DNA-PK inhibition promotes the DNA damage response induced by M1 virus, leading to increased tumour cell apoptosis. Together, our study identifies the combination of DNA-PKI and OV M1 as a potential treatment for cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang 421001, China; Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, China.
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.
- School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Guangzhou Virotech Pharmaceutical Co., Ltd, Guangzhou 510663, China.
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Natural Science Foundation
Zitieren
APA
Xiao, X., Liang, J., Huang, C., Li, K., Xing, F., Zhu, W., Lin, Z., Xu, W., Wu, G., Zhang, J., Lin, X., Tan, Y., Cai, J., Hu, J., Chen, X., Huang, Y., Qin, Z., Qiu, P., Su, X., …, & Yan, G. (2026). DNA-PK inhibition overcomes resistance to oncolytic virotherapy. Translational Research, 298, 210-225. https://doi.org/10.1016/j.trsl.2026.10.012
Vancouver
Xiao X, Liang J, Huang C, Li K, Xing F, Zhu W, et al. DNA-PK inhibition overcomes resistance to oncolytic virotherapy. Translational Research. 2026;298:210-225. doi:10.1016/j.trsl.2026.10.012
BibTeX
@article{Xiao2026,
author = {Xiao, Xiao and Liang, Jiankai and Huang, Chunlong and Li, Kai and Xing, Fan and Zhu, Wenbo and Lin, Ziqing and Xu, Wencang and Wu, Guangen and Zhang, Jifu and Lin, Xi and Tan, Yaqian and Cai, Jing and Hu, Jun and Chen, Xueqin and Huang, Youwei and Qin, Zixi and Qiu, Pengxin and Su, Xingwen and Chen, Lijun and Lin, Yuan and Zhang, Haipeng and Yan, Guangmei},
title = {DNA-PK inhibition overcomes resistance to oncolytic virotherapy},
journal = {Translational Research},
year = {2026},
volume = {298},
pages = {210--225},
doi = {10.1016/j.trsl.2026.10.012}
}
EUVIMED